Economic evaluation of parasitic diseases: A critique of the internal and external validity of published studies

Tropical Medicine and International Health

Volumn 5, Issue 4, 2000, Pages 237-249

  Walker, Damian ^a   Fox Rushby, Julia ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NONE

Author keywords

Cost effectiveness; Developing countries; Economic evaluation; Parasitic diseases; Review

Indexed keywords

DISEASE PREVALENCE; ECONOMIC ANALYSIS; LITERATURE REVIEW; PARASITIC DISEASE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HUMAN; INFECTION CONTROL; PARASITE IDENTIFICATION; PARASITOSIS;

CHILD; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HUMANS; PARASITIC DISEASES; PREVENTIVE MEDICINE; REPRODUCIBILITY OF RESULTS;

PROTOZOA;

EID: 0034024193     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2000.00546.x     Document Type: Article

References (44)

1. Australia Commonwealth Department of Health (1992). Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee Commonwealth Department, Canberra.
2. Baladi J, Menon D & Otten N (1998) Use of economic evaluation guidelines: 2 years' experience in Canada. Health Economics 7, 221-227.
3. Baltussen R, Leidl R & Ament A (1996) The impact of age on cost-effectiveness ratios and its control in decision making. Health Economics 5, 227-239.
4. Briggs A & Sculpher M (1995) Sensitivity analysis in economic evaluation. A Review of published studies. Health Economics 4, 355-371.
5. Brown C & Jackson P (1982). Public Sector Economics. Martin Robertson, Oxford.
6. Canadian Coordinating Office for Health Technology Assessment (1994). Guidelines for Economic Evaluation of Pharmaceuticals: Canada. 1st edn. CCOHTA, Ottawa.
7. Carrin G (1984). Economic Evaluation of Health Care in Developing Countries: Theory and Applications. St. Martin's Press, London.
8. Coleman PG, Goodman CA & Mills A (1998) Rebound mortality and the cost-effectiveness of malaria control: potential impact of increased mortality in late childhood following the introduction of insecticide treated nets. Tropical Medicine and International Health 4, 175-186.
9. Creese A & Parker D (1994). Cost Analysis in Primary Health Care: A Training Manual for Programme Managers. World Health Organization, Geneva.
10. Crystal R & Brewster A (1966) Cost/benefit and cost/effectiveness analyses in the health field: an introduction. Inquiry 3, 3.
11. de Ferranti D, Prescott N & Over M (1991) Affordability and the financing of health projects. In: Economics for Health Sector Analysis (ed. M Over) The World Bank, Washington, pp. 27-36.
12. Dinwiddy C & Teal F (1996). Principles of Cost-Benefit Analysis for Developing Countries. Cambridge University Press. Cambridge.
13. Drummond M, O'Brien B, Stoddart G & Torrance G (1997). Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press. Oxford.
14. Drummond M, Stoddart G & Torrance G (1987). Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press. Oxford.
15. Dunlop DW (1984) Theoretical and empirical issues in benefit identification, measurement and valuation related to parasitic disease control in poor countries. Social Science and Medicine 19, 1031-1037.
16. Evans D & Hurley S (1995) The application of economic evaluation techniques in the health sector: the state of the art. Journal of International Development 7, 503-524.
17. Evans DB, Azene G & Kirigia J (1997) Should governments subsidize the use of insecticide-impregnated mosquito nets in Africa? Implications of a cost-effectiveness analysis. Health Policy and Planning 12, 107-114.
18. Gold M, Siegel J, Russell L & Weinstein W (1996). Cost-Effectiveness in Health and Medicine. Oxford University Press. Oxford.
19. Haddix A, Teutsch S, Phaedra A & Dunet D (1996). Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. Oxford University Press. Oxford.
20. Jamison D, Mosley W, Measham A & Bobadilla J (1993). Disease Control Priorities in Developing Countries. Oxford University Press. New York.
21. Janowitz B & Bratt JH (1994) Methods for Costing Family Planning Services. United Nations Population Fund, New York.
22. Jefferson T, Smith R, Yee Y, Drummond M, Pratt M & Gale R (1998) Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and The Lancet. Journal of the American Medical Association 280, 275-277.
23. Kumaranayake L, Pepperall J, Goodman H & Mills A (1998). Costing Guidelines for HIV/AIDS Prevention Strategies A companion Volume to: Cost analysis in primary health care: A training manual for programme managers. Health Economics and Financing Programme, London School of Hygiene and Tropical Medicine, London.
24. Mason J (1997) The generalisability of pharmacoeconomic studies. Pharmacoeconomics 11, 503-514.
25. Mason J & Drummond M (1995) The DH register of cost-effectiveness studies: content and quality. Health Trends 27, 50-56.
26. Mills A (1985) Survey and examples of economic evaluation of health programmes in developing countries. World Health Statistics Quarterly 38, 402-431.
27. Mills A (1992) The economic evaluation of malaria control technologies: the case of Nepal. Social Science and Medicine 34, 965-972.
28. Mills A (1993) Is malaria control a priority? Evidence from Nepal. Health Economics 2, 333-347.
29. Mills A & Thomas M (1984) Economic evaluation of health programmes in developing countries: a review and selected annotated bibliography. London School of Hygiene and Tropical Medicine, London.
30. Paalman M, Bekedam H, Hawken L & Nyheim D (1998) A critical review of priority setting in the health sector: the methodology of the 1993 World Development Report. Health Policy and Planning 13, 13-31.
31. Panicker KN, jayasree M & Krishnamoorthy K (1992) A cost benefit analysis of fish culture strategy towards the control of mansonioides in Shertallai, Kerala state. Indian Journal of Medical Research 95, 157-160.
32. Pett M (1997) Non Parametric Statistics for Health Care Research, Statistics for Small Samples and Unusual Distributions Sage Publications. London.
33. Phillips MA, Mills A & Dye C (1993). Guidelines for Cost-Effectiveness Analysis of Vector Control WHO, Geneva.
34. Politi C, Carrin G, Evans D, Kuzoe FA & Cattand PD (1995) Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda. Health Economics 4, 273-287.
35. Prost A & Prescott N (1984) Cost-effectiveness of blindness prevention by the Onchocerciasis Control Programme in Upper Volta. Bulletin of the World Health Organization 62, 795-802.
36. Tengs TO, Adams ME, Pliskin JS et al. (1995) Five hundred life-saving interventions and their cost-effectiveness. Risk Analysis 15, 369-390.
37. The World Bank (1993) World Development Report: Investing in Health. Oxford University Press. New York.
38. Todaro M (1994). Economic Development. Longman Publishing. New York.
39. Udvarhelyi IS, Colditz GA, Rai A & Epstein AM (1992) Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Annals of Internal Medicine 116, 238-244.
40. Weinstein MC & Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 296, 716-721.
41. World Health Organization (1979). Expanded Programme on Immunization: Costing Guidelines WHO, Geneva.
42. World Health Organization (1986) Major parasitic infections: a global review. World Health Statistics Quarterly 39, 145-160.
43. World Health Organization (1988) Estimating costf for cost-effectiveness analysis. Guidelines for Managers of Diarrboeal Diseases Control Programmes WHO, Geneva.
44. World Health Organization (1999). Generic Protocols for Cost and Cost-Effectiveness Analysis of TB Diagnosis and Treatment Services WHO, Geneva.